Kennedy Capital Management’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Kennedy Capital Management’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-10,602	Closed	-$1.24M	–	766
2017 Q2	$1.24M	Sell	10,602 -52,605	-83%	-$6.53M	0.02%	632
2017 Q1	$7.8M	Buy	63,207 +15,360	+32%	+$2.01M	0.14%	250
2016 Q4	$6.52M	Buy	47,847 +21,604	+82%	+$3.84M	0.11%	312
2016 Q3	$5.22M	Sell	26,243 -6,414	-20%	-$1.1M	0.1%	354
2016 Q2	$4.23M	Buy	32,657 +15,024	+85%	+$1.67M	0.09%	393
2016 Q1	$1.65M	Buy	17,633 +3,274	+23%	+$356K	0.03%	618
2015 Q4	$2.91M	Buy	14,359 +958	+7%	+$171K	0.06%	500
2015 Q3	$1.95M	Buy	+13,401	New	+$2.46M	0.04%	576

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Kennedy Capital Management's BLCM Position: Q3 2017 in Review

Kennedy Capital Management sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2017, closing a stake of 10,602 shares — an estimated $1.24M sold.

Kennedy Capital Management first reported a position in BLCM in Q3 2015 and held it in 8 quarters. The position peaked at $7.8M in Q1 2017. 88 funds tracked by Wall St. Rank hold BLCM as of Q3 2017.

Kennedy Capital Management reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
Kennedy Capital Management sold 10,602 Bellicum Pharmaceuticals, Inc. shares in Q3 2017, an estimated $1.24M.
Kennedy Capital Management first reported a position in Bellicum Pharmaceuticals, Inc. in Q3 2015 and held it in 8 quarters.
Kennedy Capital Management's Bellicum Pharmaceuticals, Inc. position peaked at $7.8M in Q1 2017.
88 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2017.

Based on Kennedy Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.